Today, we are discussing dihydroquercetin (DHQ), also known as taxifolin. Frankly, this ingredient is mentioned fairly often in the industry, but almost always as a side note—referred to as “quercetin’s upgraded version” boasting stronger antioxidant activity, better water solubility, and higher bioavailability.
That statement is not false, but DHQ’s own story has never really been told on its own merits.
Why? I’ve taken the time to re-examine the evidence on this compound, and there are some interesting findings.
A Protagonist Often Treated as “Quercetin’s Relative”
Dihydroquercetin and quercetin are indeed from the same flavonoid family, but they differ in a key structural detail: the C-ring of DHQ is saturated (quercetin has a double bond in the C-ring), meaning DHQ carries two additional hydrogen atoms.
This subtle structural change leads to a cascade of practical differences:
– Significantly improved water solubility. Quercetin is a lipophilic flavonoid with very poor water solubility at room temperature. Native free-form quercetin has low oral bioavailability. Most commercial quercetin supplements require solubilizers or the preparation of quercetin-phospholipid complexes to improve dissolution and enhance absorption.
DHQ has markedly better water solubility than quercetin, with much higher solubility in pure water at ambient temperature. Nevertheless, technologies like microencapsulation are still needed to further boost its bioavailability.
– Greater stability. Quercetin degrades readily in alkaline environments, becoming noticeably unstable at pH >7. DHQ remains stable across a pH range of 3–9, offering much wider tolerance during storage and processing.
– Indeed stronger antioxidant activity. This is the most frequently cited advantage – many in vitro studies show that DHQ’s free radical scavenging capacity is 5–10 times that of quercetin. However, a caveat is necessary: these figures come from in vitro experiments. How much of this advantage translates into the human body is not fully supported by high-quality clinical data. We should not take the “10x stronger” claim literally. It is more accurate to say that DHQ ranks among the top in its class for antioxidant activity.
Another important background point: DHQ is not a human metabolite of quercetin. It is a naturally occurring compound found independently in nature, primarily in the roots of Larix gmelinii (Dahurian larch), and also in maritime pine, Siberian spruce, and other sources. The traditional producing region is Siberia in Russia. In China, the main supply comes from plantation-grown larch in the northeast. Russia is also the first country to have extensively studied DHQ, incorporating it into its national pharmacopoeia and related clinical application guidelines.
Preclinical research has examined DHQ’s effects on vascular permeability and microcirculation-related parameters. These observations are from preclinical research and are not product claims.
These data and applications differ from the generic antioxidant narrative common in China – in its country of origin, DHQ’s positioning leans more toward vascular-related research than vague “antioxidant” claims.
The Underestimated Regulatory Milestone of 2021
Regulatory progress for DHQ has actually moved faster than the ingredient’s market popularity would suggest.
China: Approved as a Novel Food Ingredient in 2021. In April 2021, China’s National Health Commission (NHC) officially approved DHQ as a novel food ingredient (Announcement No. 5 of 2021), with a recommended intake ≤100 mg/day. The scope and maximum permitted use levels are: beverages (20 mg/L), fermented milk and flavored fermented milk (20 mg/kg), and cocoa products, chocolate and chocolate products (70 mg/kg). The approval process took three years from filing in April 2018 to final clearance. This pace is normal for functional ingredients, but it has opened a legitimate door for DHQ in the food and dietary supplement sectors – with clear regulations and documented compliance, downstream brand development faces no legal obstacles.
International: Regulatory pathways already established in multiple countries. In 2017, the European Union approved DHQ as a novel food ingredient for the EU market. In the US and Russia, DHQ was initially regulated as a pharmaceutical ingredient and later expanded into food applications. Additionally, Japan, South Korea, Thailand, Canada, and other countries have approved its use in pharmaceuticals, functional foods, special dietary foods, and cosmetics.
Japan: Functional Food Labeling has already been achieved. Under Japan’s(earlier-adopted) system for Functional Food Labeling, several DHQ-containing products have obtained approval with health claims covering multiple areas, including: helping to relieve mental stress and helping to maintain visual memory. The proposed health claims are supported by research data. For example, one claim addresses the reduction of short-term mental fatigue in women performing repetitive tasks that require concentration and thinking. Another claim addresses the maintenance of visual memory, which tends to decline with age in healthy middle-aged and elderly individuals.
Notably, these functional claims focus on cognitive and mental health – not the traditional antioxidant space. This represents the actual market positioning of DHQ in Japan.
It is worth observing that in international markets, especially Japan, some products deliver health effects that differ significantly from those seen in China and other regions – this is a valuable reference.
Why Hasn’t DHQ Taken Off?
Given all this, why has DHQ failed to gain traction in the Chinese market? Here are my thoughts.
First, the name is a disadvantage. The name “dihydroquercetin” inherently sounds dependent – as if it is an accessory or a modified version of quercetin. Consumers cannot remember it and do not bother to differentiate. In contrast, names like “ergothioneine” or “resveratrol” are also hard to pronounce, but at least they do not carry the stigma of “what is this a knockoff of?”
Second, raw material source constraints – upstream supply is inherently limited. DHQ is mainly extracted from larch tree roots. The suitable high-yield tree species are concentrated in Siberia and the Changbai Mountains region. These trees have long growth cycles. Raw material harvesting is also subject to strict forestry regulations and environmental protection policies, as well as harvest quotas. Coupled with low extraction yields, the capacity for high-quality raw material production cannot expand rapidly. This fundamentally limits the large-scale development of the industry.
Third, production purification is difficult, keeping overall manufacturing costs high. The purification process for DHQ is complex. Achieving pharmaceutical-grade or high-purity food-grade standards requires multiple refining steps, leading to high energy consumption and environmental treatment costs. The final raw material price is much higher than that of ordinary quercetin and other similar flavonoids. This high price makes most end-product brands cautious when considering DHQ in their formulations.
Fourth, market awareness is weak – consumer knowledge is poor. Industry insiders are familiar with DHQ’s effects on vascular protection and capillary repair, but there has been a serious lack of promotion and education directed at the general consumer. Consumers are generally only familiar with quercetin, knowing very little about the efficacy or absorption advantages of DHQ. Without a foundation of consumer awareness, spontaneous market demand is hard to create. Moreover, compared to quercetin, the price barrier of DHQ is real – this cost difference ultimately reaches the consumer, and paying more for something “supposedly better” is a significant decision hurdle.
But DHQ Has Its Own Moat
Having outlined the constraints, let’s talk about where this ingredient truly excels.
Natural water solubility is a core advantage. Given that most quercetin products rely on solubilizing technologies to enhance absorption, DHQ’s inherent water solubility is a tangible plus in formulation development and consumer experience. Particularly for people with sensitive gastrointestinal systems – where high doses of quercetin can cause discomfort – DHQ is milder and addresses a real unmet need in this niche population.
Vascular health offers a unique differentiation opportunity. Currently, the mainstream antioxidant space in China is heavily focused on anti-aging and skin health. The vascular protection and capillary health niche is relatively less crowded. If DHQ establishes a clear “expert” positioning in this area, it can pursue differentiated competition rather than fighting an intense “red ocean” battle in anti-aging.
Cosmetics is a channel worth watching. Antioxidation is a perennial theme in cosmetic ingredients. However, domestic brands tend to follow highly homogenized choices – niacinamide, vitamin C, astaxanthin – mixed and matched repeatedly. DHQ is still rarely used in cosmetic-grade ingredients, offering a first-mover advantage. The key is finding the right brand to lead and educate the market in this direction.
Closing Thoughts
After writing this article, my feeling is: dihydroquercetin is a powerhouse held back by its name.
It has a solid scientific foundation, a clear regulatory status, and performance advantages that differentiate it from similar ingredients – yet it has never built its own consumer mindshare.
In the functional ingredients race, research data gets you a ticket, but it does not guarantee market success. Breaking out always requires a brand that can tell the story clearly and sell the product effectively.
DHQ has been waiting for that moment for four years. Perhaps what it needs is not more papers, but a brand that truly cares.
References
-
Liu, B., Sun, J., Han, L., Yin, Y., & Meng, X. (2025). Preparation of dihydroquercetin microcapsules with sodium starch octenyl succinate and maltodextrin as wall materials to improve stability, solubility and bioaccessibility. Food Chemistry, 493, 146072.
-
[Review on pharmacological effects of dihydroquercetin], Drug Evaluation Research, Vol. 47, No. 5, May 2024.
-
Orlova S V, Tatarinov V V, Nikitina E A, et al. Bioavailability and Safety of Dihydroquercetin (Review)[J]. Pharmaceutical Chemistry Journal, 2022, 55(11): 1133-1137.
-
Dihydroquercetin Novel Food Ingredient Approval Document (National Health Commission Announcement No. 5 of 2021)